Steven F. Bolling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Steven F. Bolling has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
Hua Lin
5 shared publications- Ara Kirakosyan
University of Michigan
4 shared publications Ru-Qi Wei
Thoracic Surgery Research Laboratory, University of Michigan Medical Center, Ann Arbor, Michigan, 48109, USA
4 shared publicationsCharles F. Schwartz
Section of Thoracic Surgery, The University of Michigan Medical Center, Ann Arbor, Michigan
3 shared publications- Jason H. Rogers
University of California, Davis Medical Center
3 shared publications - Francis D. Pagani
Department of Cardiac Surgery, University of Michigan Medical School, Ann Arbor, Michigan
2 shared publications
Latest Publications
- 1 October 2025
- Published by Springer Nature
- p. 61-81
Grapes and Metabolic Syndrome
- Open Access
- 1 January 2018
- Published by Compuscript, Ltd. in Cardiovascular Innovations and Applications
- Vol. 2 (4) , 451-457
Functional Tricuspid Regurgitation and Ring Annuloplasty Repair
Functional tricuspid regurgitation (TR) primarily arises from asymmetric dilation of the tricuspid annulus in the setting of right ventricular dysfunction and enlargement in response to left-sided myocardial and valvular abnormalities. Even if the TR is not severe at the time of mitral valve surgery, it can worsen and even appear late after successful mitral valve surgery, which portends a poor prognosis. Despite data demonstrating inferior outcomes in the presence of residual TR, surgical repair for functional TR remains underused. Acceptance of TR, in the presence of tricuspid annular dilation, may be unacceptable. Surgical repair should consist of placement of a rigid or semirigid annular ring, which has been shown to provide superior durability as compared with suture and flexible band techniques. Finally, percutaneous annuloplasty for correction of functional TR may allow treatment of patients with recurrent TR at high risk of reoperation.
- 1 January 2018
- Published by Compuscript, Ltd. in Cardiovascular Innovations and Applications
- Vol. 2 (4) , 451-457
Open AccessFunctional Tricuspid Regurgitation and Ring Annuloplasty Repair
Functional tricuspid regurgitation (TR) primarily arises from asymmetric dilation of the tricuspid annulus in the setting of right ventricular dysfunction and enlargement in response to left-sided myocardial and valvular abnormalities. Even if the TR is not severe at the time of mitral valve surgery, it can worsen and even appear late after successful mitral valve surgery, which portends a poor prognosis. Despite data demonstrating inferior outcomes in the presence of residual TR, surgical repair for functional TR remains underused. Acceptance of TR, in the presence of tricuspid annular dilation, may be unacceptable. Surgical repair should consist of placement of a rigid or semirigid annular ring, which has been shown to provide superior durability as compared with suture and flexible band techniques. Finally, percutaneous annuloplasty for correction of functional TR may allow treatment of patients with recurrent TR at high risk of reoperation.
- 1 October 2016
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 9 (19) , 2048-2049
Percutaneous Mitral Repair
- 1 October 2016
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 9 (19) , 2048-2049
Percutaneous Mitral Repair
- 1 August 2016
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 102 (2) , 526
Invited Commentary
- 1 August 2016
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 102 (2) , 526
Invited Commentary
- 1 January 2015
- Published by Springer Nature
- p. 1201-1220
Pathophysiology and Management of Functional Tricuspid Regurgitation
- 1 January 2015
- Published by Springer Nature
- p. 1201-1220
Pathophysiology and Management of Functional Tricuspid Regurgitation
- 1 March 2014
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 29 (2) , 133-139
Surgical approach to functional tricuspid regurgitation
Functional tricuspid regurgitation (FTR) is an important clinical entity that is encountered frequently during the operative management of left-sided heart valve disease, particularly in the setting of mitral regurgitation. Failure to recognize the importance of FTR during mitral valve surgery may result in inferior early and late outcomes because of the progression of tricuspid regurgitation and right heart failure. In this review, attention is focused on recent literature, which increasingly supports the use of corrective tricuspid valve annuloplasty, and the growing consensus that FTR or tricuspid annular dilation should be more aggressively addressed at the time of cardiac surgery. The European Society of Cardiology and the European Association for Cardiothoracic Surgery (ESC/EACTS) 2012 guidelines recommend a more proactive approach to tricuspid regurgitation correction and highlight the shifting consensus toward more aggressive surgical therapy. Rigid annuloplasty rings should be used in favor of flexible bands or DeVega-style repairs. Preoperative determinants of clinical outcomes now include echocardiographic parameters of tricuspid valve tenting area, and associated right ventricular size and function. Despite data demonstrating inferior outcomes in the presence of residual tricuspid regurgitation after cardiac surgery, surgical repair for FTR appears to be underutilized. Increased recognition and correction of tricuspid regurgitation at the time of surgery is increasingly supported by published guidelines, although randomized prospective data are needed to bolster current recommendations.
- 1 March 2014
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 29 (2) , 133-139
Surgical approach to functional tricuspid regurgitation
Functional tricuspid regurgitation (FTR) is an important clinical entity that is encountered frequently during the operative management of left-sided heart valve disease, particularly in the setting of mitral regurgitation. Failure to recognize the importance of FTR during mitral valve surgery may result in inferior early and late outcomes because of the progression of tricuspid regurgitation and right heart failure. In this review, attention is focused on recent literature, which increasingly supports the use of corrective tricuspid valve annuloplasty, and the growing consensus that FTR or tricuspid annular dilation should be more aggressively addressed at the time of cardiac surgery. The European Society of Cardiology and the European Association for Cardiothoracic Surgery (ESC/EACTS) 2012 guidelines recommend a more proactive approach to tricuspid regurgitation correction and highlight the shifting consensus toward more aggressive surgical therapy. Rigid annuloplasty rings should be used in favor of flexible bands or DeVega-style repairs. Preoperative determinants of clinical outcomes now include echocardiographic parameters of tricuspid valve tenting area, and associated right ventricular size and function. Despite data demonstrating inferior outcomes in the presence of residual tricuspid regurgitation after cardiac surgery, surgical repair for FTR appears to be underutilized. Increased recognition and correction of tricuspid regurgitation at the time of surgery is increasingly supported by published guidelines, although randomized prospective data are needed to bolster current recommendations.
- 1 December 2012
- Published by Springer Nature
- p. 1-11
Mitral Valve Anatomy and Current Surgical and Percutaneous Approaches to Mitral Regurgitation
- 1 December 2012
- Published by Springer Nature
- p. 1-11
Mitral Valve Anatomy and Current Surgical and Percutaneous Approaches to Mitral Regurgitation
- Open Access
- 4 October 2012
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 42 (6) , 915-917
What to do with functional mitral regurgitation: what do we really know and how can we find out?
Managing heart failure patients with left ventricular dysfunction-associated mitral regurgitation (functional mitral regurgitation or FMR) is challenging and requires a multidisciplinary approach. Optimal medical therapy (OMT) with vigilant outpatient surveillance, cardiac resynchronization therapy (CRT) and myocardial revascularization can all have positive impacts on quality of life, and perhaps even survival. Since as many as 30% of individuals with heart failure have moderate–severe mitral regurgitation (MR), it is mechanistically appealing to postulate that correcting MR, whether by surgery or transcatheter MitraClip therapy, should benefit these patients. However, data supporting FMR correction are largely observational. The current American College of Cardiology/American Heart Association (ACC/AHA) guidelines give mitral valve repair in patients with symptomatic severe left ventricular dysfunction a Class IIa (level of evidence C) recommendation [1]. The European Society of Cardiology (ESC) guidelines also cite limited data (level of evidence C) supporting mitral valve correction and give primarily Class IIa/b recommendations for the surgical correction of MR in the setting of left ventricle (LV) dysfunction with or without coronary artery disease and planned CABG [2]. MitraClip therapy, by virtue of its percutaneous delivery, may offer improved safety when compared with surgical mitral valve repair in patients with predominantly degenerative MR, but at the expense of far less effective MR reduction [3]. It is felt, however, that MitraClip therapy may be ideally suited for the treatment of higher- or extreme-surgical-risk FMR patients in whom other treatment options are limited. What then, does the accompanying report add to our understanding of applying surgery or MitraClip to patients with FMR? And how does it help us answer the question of ‘what to do with FMR?’
- 4 October 2012
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 42 (6) , 915-917
Open AccessWhat to do with functional mitral regurgitation: what do we really know and how can we find out?
Managing heart failure patients with left ventricular dysfunction-associated mitral regurgitation (functional mitral regurgitation or FMR) is challenging and requires a multidisciplinary approach. Optimal medical therapy (OMT) with vigilant outpatient surveillance, cardiac resynchronization therapy (CRT) and myocardial revascularization can all have positive impacts on quality of life, and perhaps even survival. Since as many as 30% of individuals with heart failure have moderate–severe mitral regurgitation (MR), it is mechanistically appealing to postulate that correcting MR, whether by surgery or transcatheter MitraClip therapy, should benefit these patients. However, data supporting FMR correction are largely observational. The current American College of Cardiology/American Heart Association (ACC/AHA) guidelines give mitral valve repair in patients with symptomatic severe left ventricular dysfunction a Class IIa (level of evidence C) recommendation [1]. The European Society of Cardiology (ESC) guidelines also cite limited data (level of evidence C) supporting mitral valve correction and give primarily Class IIa/b recommendations for the surgical correction of MR in the setting of left ventricle (LV) dysfunction with or without coronary artery disease and planned CABG [2]. MitraClip therapy, by virtue of its percutaneous delivery, may offer improved safety when compared with surgical mitral valve repair in patients with predominantly degenerative MR, but at the expense of far less effective MR reduction [3]. It is felt, however, that MitraClip therapy may be ideally suited for the treatment of higher- or extreme-surgical-risk FMR patients in whom other treatment options are limited. What then, does the accompanying report add to our understanding of applying surgery or MitraClip to patients with FMR? And how does it help us answer the question of ‘what to do with FMR?’